The value of sex hormones and sex hormone-binding globulin in metabolic dysfunction-associated fatty liver disease among boys with obesity

The value of sex hormones and sex hormone-binding globulin in metabolic dysfunction-associated fatty liver disease among boys with obesity

ObjectiveThis study aims to investigate the relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and sex hormones and sex hormone-binding globulin (SHBG) in boys with obesity.MethodsRetrospective analysis of metabolic indicators and sex hormone levels in boys with obesit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying Wang, Shuyi Yang, Suming Zhang, Ye Yang, Siqing Li, Meiyu Zhang, Xiaona Li, Hua Bai, Peiliang Luo, Yingdi Yuan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Endocrinology
Subjects:	childhood obesity metabolic dysfunction-associated fatty liver disease (MAFLD) non-alcoholic fatty liver disease (NAFLD) sex hormone-binding globulin (SHBG) testosterone
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1446049/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Genome-wide association study of the fatty liver index in the Taiwanese population reveals shared and population-specific genetic risk factors across ethnicities
by: Pei Pei Lau, et al.
Published: (2025-02-01)

Metabolic Profiles of the Gut Microbiota in Patients with Different Stages of Metabolism Dysfunction-Associated Fatty Liver Disease
by: X. Cao, et al.
Published: (2024-10-01)

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study
by: I. Yu. Pirogova, et al.
Published: (2018-09-01)

Global research trends in Chinese medicine for the treatment of non-alcoholic fatty liver disease (NAFLD): A bibliometric study
by: Kangjie li, et al.
Published: (2025-03-01)

Metabolic and Genetic Determinants of Lipid Metabolism Disruption in Non-Alcoholic Fatty Liver Disease
by: O. Yu. Kytikova, et al.
Published: (2020-05-01)

Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
by: Aleksey O. Bueverov
Published: (2019-03-01)

The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
by: Hongsheng Li, et al.
Published: (2025-03-01)

Intrahepatic Cholestasis in Non-Alcoholic Fatty Liver Disease: Pathogenesis and Role of Ademetionine in Treatment
by: Ye. N. Shirokova
Published: (2023-08-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study
by: Hui Liu, et al.
Published: (2025-01-01)

Histopathological analysis of the liver in hypercholesterolemia rats treated with Dillenia serrata fruits
by: Tien, et al.
Published: (2022-12-01)

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: A. E. Bagriy, et al.
Published: (2021-06-01)

Pathogenic role of lipids in non-alcoholic fatty liver disease
by: Yu. O. Shulpekova
Published: (2012-02-01)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
by: V. T. Ivashkin, et al.
Published: (2022-12-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Investigation of the healing effects of Afyon Province hot spring waters on experimentally-induced fatty liver in mice
by: Bülent Elitok, et al.
Published: (2020-09-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease
by: T. S. Krolevets, et al.
Published: (2020-12-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Electrical and Viscoelastic Parameters of Erythrocytes as a Part of Diagnostic Models for Differentiating Fatty Liver Disease of Mixed Genesis from Non-Alcoholic and Alcohol-Related Fatty Liver Disease
by: M. V. Kruchinina, et al.
Published: (2024-08-01)

Spinach ameliorates dietary oxidized tallow-induced NAFLD by regulating inflammatory cytokines, peroxisome proliferator-activated receptors, and antioxidant systems
by: Neelab, et al.
Published: (2025-02-01)

Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Mediterranean diet improves liver health but does not protect against azoxymethane-induced colon tumorigenesis compared to Western diet in A/J mice
by: Weimin Guo, et al.
Published: (2025-03-01)

The development of a food-group, tree classification method and its use in exploring dietary associations with metabolic dysfunction-associated Steatotic liver disease (MASLD) and other health-related outcomes in a UK population
by: Amina A. Alawadi, et al.
Published: (2025-03-01)

Prevalence of non-alcoholic fatty liver disease at obesity and its interrelation with cardio-vascular disease and 2nd type diabetes mellitus risk factors
by: G. A. Melnichenko, et al.
Published: (2012-04-01)

Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content
by: Haoxiang Zhu, et al.
Published: (2025-01-01)

Helicobacter pylori Infection and Hepatobiliary Pathology
by: S. V. German, et al.
Published: (2018-09-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Iron-regulatory liver hormone hepcidin and its place in the system of congenital immunity
by: O. A. Smirnov
Published: (2010-11-01)

Structural and functional properties of fava bean albumin, globulin and glutelin protein fractions
by: Timilehin David Oluwajuyitan, et al.
Published: (2025-01-01)

Dietary and lifestyle indices for hyperinsulinemia and odds of MAFLD in overweight and obese children and adolescents
by: Ali Nikparast, et al.
Published: (2025-02-01)

Phenotypes of Non-Alcoholic Fatty Liver Disease in Different Regions of the Russian Federation, Diagnostic and Therapeutic Approach in Clinical Practice
by: V. T. Ivashkin, et al.
Published: (2023-08-01)

Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: P. Ebrahimpour, et al.
Published: (2024-03-01)

Lipotoxicity and metabolic disorders at obesity
by: V. T. Ivashkin, et al.
Published: (2010-02-01)

Non-Alcoholic Fatty Liver Disease in Cardiac Patients with Overweight and Obesity
by: I. V. Logacheva, et al.
Published: (2019-01-01)

Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
by: R. V. Maslennikov, et al.
Published: (2018-09-01)

Gut Microbiota and its Metabolites in Pathogenesis of NAFLD
by: M. S. Reshetova, et al.
Published: (2023-02-01)

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01)